Evolution Metals & Technologies Corp. Regains Compliance with Nasdaq Listing Rule Following Previously Received Notice and Filing of Quarterly Report on Form 10-Q

Evolution Metals & Technologies (Nasdaq: EMAT) said it signed a supply agreement with Senri Trading to buy bulk neodymium-praseodymium (NdPr) metal from SRE Vietnam, a Tokai subsidiary, sourced entirely outside China. EMAT links the contract to ramping rare-earth magnet production to ~10,000 tons per year and cites upcoming U.S. defense rules restricting Chinese-origin magnets from Jan. 1, 2027.

Evolution Metals & Technologies (EMAT) shares fell about 12% after the company reported Q1 2026 results, according to S&P Global Market Intelligence. The report showed revenue of $1.88 million and a net loss of $0.72 per share, versus a $0.04 loss per share a year earlier. The company also said it signed a purchase agreement for 13 magnet production machines, targeting ~10,000 metric tons annual capacity.

Snap (SNAP) shares fell 12.4% in pre-market trading to $4.74, driven by a court ruling against social media liability, insider selling by CTO Robert Murphy, and cautious analyst sentiment despite better-than-expected Q2 results. The 9th U.S. Circuit Court of Appeals allowed lawsuits alleging Snapchat's design maximizes engagement among minors to proceed, creating legal uncertainty. Murphy sold 4 million shares for $21.6 million, adding to negative sentiment. Analysts lowered price targets but ma

S&P Global Ratings revised Emergent BioSolutions' outlook to negative, citing lower revenue guidance due to competition in the naloxone market. The company reduced its 2026 revenue and EBITDA guidance by $80M and $25M, respectively, due to weaker NARCAN sales. S&P noted potential refinancing risks for Emergent's $440M unsecured notes maturing in 2028, with declining revenue and uncertain growth prospects.

The FDA approved Orzeyful, a narcolepsy type 1 drug by Takeda, targeting the root cause by mimicking orexin. Clinical trials showed improved wakefulness, sleep, and fewer cataplexy episodes. Takeda's CEO called it a new chapter for treatment. The drug may also have applications for ADHD and Parkinson's. According to experts, more research is needed, as not all patients lack orexin.

China is removing a customized version of Windows 10 from government systems earlier than planned, citing data-security concerns. The move supports China's push to replace foreign tech with domestic alternatives. Microsoft stated it was unaware of any security incidents. The OS, developed by C&M Information Technologies, was set to retire in 2027 but is now being uninstalled ahead of schedule.